

ELIOS: A Proven Solution in Interventional Glaucoma¹


Seamlessly integrates
into your practice

- Proven, consistent IOP reduction for up to 8 years¹
- Up to 80% of patients medication-free 1 year post-procedure²
- Preserves the natural angle without the use of an implant³
- **Suitable for Phaco+ and standalone use³**



Glaucoma Patients Face Significant Challenges

Addressing these challenges requires a solution that simplifies glaucoma care and improves patient outcomes.



20%

of cataract
patients also have
glaucoma or ocular
hypertension (OHT)⁴



66%

of glaucoma
patients struggle
with compliance⁵




62%

experience
adverse effects⁶

**ELIOS may be the minimally invasive, implant-free solution
your glaucoma patients with cataract need**

Phaco+MIGS has demonstrated beneficial impact on the disease



Slow rate of progression^{1,7}



Stabilise IOP⁷



Reduce dependence on drop therapy^{1,7}



Reduce requirement for secondary surgical intervention^{3,7}

“The justification [for Phaco+] comes from the increasing evidence of the damaging impact of long-term drop use and, certainly, the damaging impact of long-term preservative use.”

PROF GUS GAZZARD
MOORFIELD'S EYE HOSPITAL, LONDON, UK



ELIOS: A Trusted, implant-free Solution for Glaucoma Care

ELIOS uses high-precision excimer laser technology to create ten microchannels in the trabecular meshwork, enhancing natural outflow into Schlemm's canal.¹

- Safe and minimally invasive⁸
- Preserves natural angle anatomy¹⁰



Scan the code to watch
how ELIOS works.



Long-Term Data and Real-World Outcomes

ELIOS delivers consistent IOP reduction and sustained patient outcomes, backed by robust clinical data.


Proven Safety and Long-Term Efficacy

Long-term outcomes backed by real-world experience:


> **8 years:** Sustained IOP reduction >20%¹

> Up to **80%:** Medication-free at 12 months²


IOP Reduction (>20%) Maintained for up to 8 Years¹



Long-Term Microchannel Patency (31 months post-op)



80% of Patients Medication-Free at 1 Year²



Consistent, Predictable Outcomes You Can Trust


ELIOS – A Trusted Partner in Glaucoma Care



Proven clinical experience^{9,10}

8⁺

8+ years of follow-up data¹



More than 10,000 eyes treated¹¹

For patients with concomitant glaucoma and cataract, ELIOS is a procedure that...



- > ... consolidates the two procedures into one⁹
- > ... may alleviate the burden of daily eye drops¹
- > ... may provide significant & sustained long-term IOP reduction¹
- > ... does not involve the use of an implant in the eye¹⁰


For doctors who care for glaucoma patients, ELIOS




- > ... is highly adoptable¹⁰
- > ...can be conveniently integrated into standard OR routines¹²
- > ... offers flexibility as a combined Phaco+ or standalone procedure¹²

Getting Started with ELIOS: Your Next Step in Glaucoma Care

Three simple steps to get started with ELIOS.



ELIOS - With you at every step



Implant-free¹

Non-thermal excimer laser²

Suitable for Phaco+ or Standalone treatment³

elios - it just makes sense.

1. Riesen M, Funk J, Töteberg-Harms M. *Graefes Arch Clin Exp Ophthalmol*. 2022 May.
2. Moreno Valladares A, Puerto Amorós N, Mendez Llatas M, Pazos López M, Ahmed IIK. *Arch Soc Esp Ophthalmol (Engl Ed)*. 2021 Mar.
3. Berlin MS, Shakibkhou I, Tilakaratna N, Giers U, Groth SL. *J Cataract Refract Surg*. 2022 Jul.
4. Hughes R, Aristodemou P, Sparrow JM, Kaye S. *Br J Ophthalmol*. 2021 Nov.
5. Omoti AE, Ukponmwan CU. *Seguimiento Farmacoterapéutico*. 2005.
6. Nordmann JP, Auzanneau N, Ricard S, et al. *Health Qual Life Outcomes*. 2003.
7. Glaucoma Today (2023) Routine Phaco+MIGS: Are We There Yet? Available at: (<https://glaucomatoday.com/articles/2023-july-aug-supplement2/routine-phaco-migs-are-we-there-yet>) [Accessed January 2025].
8. Quaranta L, Riva I, Gerardi C, Oddone F, Floriani I, Konstas AG. *Adv Ther*. 2016 Jun.
9. Pidro A, Biscevic A, Pjano MA, Mravicic I, Bejdic N, Bohac M. *Acta Inform Med*. 2019 Dec.
10. Durr et al. *Eye and Vision*. 2020.
11. Data on file.
12. Töteberg-Harms M, Hanson JV, Funk J. *BMC Ophthalmol*. 2013 Jun.